A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 9, 2017

Primary Completion Date

June 26, 2018

Study Completion Date

June 26, 2018

Conditions

Hepatic Insufficiency

Interventions

DRUG

Ipatasertib

A single oral dose of 100 mg ipatasertib will be administered.

Trial Locations (3)

Clinical Pharmacology of Miami, Inc., Miami

New Orleans Center for Clinical Research, Knoxville

American Research Corporation Inc., San Antonio